Redeye provides an in-depth review of Acarix’s Q2 report and related events during and after the quarter. The quarter contained no surprises, apart from softer revenues due to the EU divestment and CADScor systems delivered under the consignment model. We have an optimistic outlook on the company’s recent news flow, which demonstrates progress in gaining a broader reimbursement coverage from US payors. We reiterate our fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/